Back

Prevalence of RV dysfunction in patients under cardiotoxic chemoterapy: a preliminary analysis

27 August 2022 (08:15 - 08:55)
Organised by:
Congress Presentation Part of: Cardio-oncology 1 Cardio-Oncology ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Sergio Maltes

Hospital Santa Cruz, Lisbon (Portugal)

5 More presentations in this session

Presentation thumbnail
The effect of ACE-I/ARBs and beta blockers on the development of cardiotoxicity in patients with breast cancer
Doctor G. Umadat (Jacksonville, US)
Abstract Slides
Presentation thumbnail
Valvular changes following anthracycline therapy: is it time to look beyond ejection fraction?
Doctor M. Laufer-Perl (Tel Aviv, IL)
Abstract Slides
Presentation thumbnail
Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis - report from an international registry
Doctor P. Guedeney (Paris, FR)
Abstract Slides
Presentation thumbnail
Emergency department cardiovascular disease encounters and associated mortality in patients with cancer: a study of 20.6 million records from the USA
Doctor O. Kobo (Hadera, IL)
Abstract Slides
Presentation thumbnail
Cardio-Oncology: a medical specialty in constant growth and evolution. the 10-year experience of the first cardio-oncology service in the United Kingdom
Doctor M. Andres (London, GB)
Abstract Slides

Access the full session

Session thumbnail
Cardio-oncology 1

The Event

Event poster

ESC Congress 2022

27 August 2022 08:15 CET
You may be interested in
thumbnail
Congress Presentation
A right ventricular function study in a group of breast cancer patients undergoing chemotherapy
22 May 2023
thumbnail
Congress Presentation
Prevalence and determinants of right ventricular dysfunction in patients with severe symptomatic high-gradient aortic stenosis
1 July 2021
thumbnail
Congress Session
Cardio-oncology: the new kid on the block for multi-modality imagers
11 May 2023
thumbnail
Congress Presentation
Cardiotoxicity of BRAF and MEK inhibitors in patients with melanoma: a real-world longitudinal study incorporating contemporary definitions and risk scores
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources